

# Vincent Caggiano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6391962/publications.pdf>

Version: 2024-02-01

11  
papers

2,679  
citations

1040018

9  
h-index

1281846

11  
g-index

11  
all docs

11  
docs citations

11  
times ranked

4073  
citing authors

#	ARTICLE	IF	CITATIONS
1	Descriptive analysis of estrogen receptor (ER)â€negative, progesterone receptor (PR)â€negative, and HER2â€negative invasive breast cancer, the soâ€called tripleâ€negative phenotype. <i>Cancer</i> , 2007, 109, 1721-1728.	4.1	1,764
2	Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004. <i>Breast Journal</i> , 2009, 15, 593-602.	1.0	257
3	Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers. <i>Journal of Cancer Epidemiology</i> , 2014, 2014, 1-11.	1.1	185
4	The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptorâ€negative, invasive breast cancer: The California Cancer Registry, 1999â€2004. <i>Cancer</i> , 2008, 112, 737-747.	4.1	153
5	Variation in breast cancer subtypes with age and race/ethnicity. <i>Critical Reviews in Oncology/Hematology</i> , 2010, 76, 44-52.	4.4	86
6	Disparities in race/ethnicity and socioeconomic status: risk of mortality of breast cancer patients in the California Cancer Registry, 2000â€2010. <i>BMC Cancer</i> , 2013, 13, 449.	2.6	78
7	Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. <i>BMC Cancer</i> , 2010, 10, 228.	2.6	69
8	Risk of mortality of node-negative, ER/PR/HER2 breast cancer subtypes in T1, T2, and T3 tumors. <i>Breast Cancer Research and Treatment</i> , 2017, 165, 743-750.	2.5	44
9	Disparities in receipt of adjuvant radiation therapy after breastâ€conserving surgery among the cancerâ€reporting regions of California. <i>Cancer</i> , 2012, 118, 2516-2524.	4.1	33
10	The influence of comorbidity on treatment and survival of tripleâ€negative breast cancer. <i>Breast Journal</i> , 2020, 26, 1729-1735.	1.0	6
11	Differences in clinicopathologic characteristics and risk of mortality between the triple positive and ER+/PR+/HER2â€ breast cancer subtypes. <i>Cancer Causes and Control</i> , 2019, 30, 417-424.	1.8	4